What Is a Tumor Board? Multidisciplinary Cancer Decisions, Clinical Practice, and Virtual Education

Cancer care rarely falls within the scope of a single specialty. Diagnosis, staging, surgery, systemic therapy, and radiation often intersect, and a decision made in one area can change what is possible in another. A tumor board is the structured multidisciplinary meeting where those perspectives come together as the treatment plan is developed.

In a recent episode of Oncology Unfiltered (Multidisciplinary Realities: Tumor Board vs Tuesday Afternoon on Oncology Data Advisor), Melissa Cutrona, MS, General Manager of i3 Health, and Matthew Hadfield, DO, attending medical oncologist at Brown University/Legorreta Cancer Center and Editor in Chief of Oncology Data Advisor, discussed how multidisciplinary tumor boards work, and what happens after the meeting concludes. For clinicians and education planners, that conversation is a useful map of both clinical practice and how tumor board-style learning can travel online.

What Is a Tumor Board?

Dr. Hadfield described tumor boards as disease-focused meetings in which specialists regularly review individual patient cases. The goal is not a lecture. It is a shared, case-level decision: what is known, what is uncertain, and what sequence of care best fits this patient now.

Why Multidisciplinary Review Matters in Oncology

This multidisciplinary approach is particularly important in oncology, where each specialty contributes to a different part of the patient's care. Pathology helps establish the diagnosis and histology, while imaging helps define the extent of disease. Surgeons assess whether resection is feasible, while medical and radiation oncologists consider where their respective therapies fit within the treatment course.

These decisions are often interconnected. When a patient is being considered for surgery, for example, the discussion may also involve whether systemic therapy should be given beforehand, whether radiation has a role, and what treatment may be appropriate after surgery. The discussion is therefore not only about which treatment to use, but also how and when each therapy should fit into the patient's overall course.

From a continuing education perspective, that sequencing conversation is also where learning happens: clinicians rehearse tradeoffs they will face again outside the conference room.

Guidelines Still Leave Room for Clinical Judgment

Dr. Hadfield noted that staging criteria and treatment guidelines can make cancer management appear relatively straightforward on paper. In practice, there are gray areas involving histology, stage, resectability, and the most appropriate treatment approach.

Guidelines remain fundamental to evidence-based care, but a patient's course does not always follow the expected pathway. A patient may develop toxicity, experience a surgical complication, or have recurrent or progressive disease. New clinical information may also emerge after the original plan has been established.

Tumor board discussion is particularly useful when several modalities need to be sequenced. Dr. Hadfield highlighted potentially resectable cancers in which systemic therapy may be given before or after surgery, with radiation incorporated when appropriate, requiring coordination across specialties.

Tumor boards do not replace established guidelines; they help clinicians apply them when an individual patient's course is more complex than the standard pathway suggests.

Reaching a Recommendation Is Only the First Step

At the end of the discussion, the group works toward a shared recommendation.

Depending on the case, this may involve additional imaging, systemic therapy before or after surgery, or evaluation by radiation oncology. Dr. Hadfield explained that the agreed-upon recommendation is formally documented.

Not every case leads to immediate agreement. Specialists may favor different approaches, and Dr. Hadfield noted that disagreements can occur. Bringing these specialists together helps the team work through different perspectives and decide on the best way to move forward with the patient's care.

Reaching a recommendation, however, is only part of the process.

A recommendation still has to be carried out. Imaging must be scheduled, pathology materials and outside records may need to be obtained, referrals completed, and treatment coordinated. Dr. Hadfield emphasized the role of nurses, nurse practitioners, and nurse navigators in helping move these plans forward.

Logistical delays can affect even a carefully planned course of treatment. These challenges are not confined to smaller centers; Dr. Hadfield noted that obtaining outside records and pathology materials can be difficult even in large academic institutions. For the patient, the value of the recommendation ultimately depends on whether the next steps can be carried out.

The Patient Still Makes the Decision

A tumor board recommendation is not necessarily the end of the decision-making process. Dr. Hadfield described situations in which specialists meet with patients after tumor board discussion to explain the proposed treatment approach, including its rationale, risks, and benefits. Ultimately, however, the patient decides whether to proceed.

Once a recommendation is made, physicians still need to ensure that the patient understands the proposed approach and the available alternatives. Clear discussion of the next steps also allows patients to recognize when an expected scan, result, or appointment has been delayed. As Dr. Hadfield emphasized, patient self-advocacy can provide an additional safeguard when communication or coordination falls short.

A Snapshot in Time, Not a Final Verdict

A particularly important point in the discussion was Dr. Hadfield's description of a tumor board recommendation as a "snapshot in time."

A patient may begin treatment with a clear sequence in mind and later develop toxicity, experience a surgical complication, or have recurrent or progressive disease. The original recommendation may then need to be reconsidered.

A change in treatment does not necessarily mean that the original plan was wrong. A patient's clinical course is not always linear, and treatment decisions must adapt as new information emerges.

Dr. Hadfield closed with a simple but important point: there is no perfect plan. Toxicity, disease progression, comorbidities, and other changes may require a previously agreed-upon strategy to be revised. The goal is to identify the best approach for that patient at that particular time.

The purpose of the tumor board is not simply to reach agreement, but to develop a coordinated plan that can be carried into practice and adjusted when the patient's course changes. Ultimately, the goal is to choose an approach that balances expected clinical benefit with safety, quality of life, and the patient's informed preferences.

How Virtual Tumor Boards Work as an Educational Format

The same multidisciplinary logic that shapes a clinical tumor board can also support virtual or online tumor board education. That format is not a substitute for a patient's care team. It is a way for clinicians to practice how those decisions are made.

In a virtual tumor board education activity, learners typically work a teaching or de-identified case through facilitated discussion across specialties. Pathology and imaging findings are made explicit. Surgical, systemic, and radiation options are sequenced against guidelines and real-world constraints. Disagreement is modeled, not hidden. As the Oncology Unfiltered conversation stressed, the story does not end at the recommendation: navigation, records, timing, and patient preference still determine whether a plan succeeds.

Done well, online tumor boards can achieve many of the educational results of sitting in the room: shared mental models across disciplines, clearer use of guidelines in gray areas, and attention to the post-meeting work that patients actually experience. The format also scales. More clinicians can join a live session or revisit an on-demand case than fit around one conference table.

Putting the Lessons to Work

Tumor boards, in clinic and as virtual education, succeed for the same reason: they make multidisciplinary judgment visible, documented, and actionable. The Oncology Unfiltered reminder still holds. The best plan is the one that can be carried out, explained to the patient, and revised when the snapshot changes.

Case-based multidisciplinary discussion teaches sequencing, disagreement, and follow-through in ways a lecture often cannot. Earning continuing education credit formalizes this learning experience, providing a concrete incentive for clinicians to dedicate time to complex clinical reasoning outside their standard clinical duties.

Frequently Asked Questions

What is a tumor board in cancer care?

A tumor board is a structured, disease-focused multidisciplinary meeting where specialists review individual patient cases and work toward a shared, case-level treatment recommendation.

Why do multidisciplinary tumor boards matter in oncology?

Pathology, imaging, surgery, systemic therapy, and radiation each shape different parts of care; tumor boards coordinate sequencing and judgment when guidelines leave gray areas.

How do tumor board recommendations get carried into clinical practice?

After the group documents a recommendation, nurses, navigators, and care teams schedule imaging, gather records, complete referrals, and coordinate treatment, and the patient still decides whether to proceed.

Can virtual or online tumor boards achieve similar results to in-person meetings?

As an educational format, virtual tumor boards help clinicians practice multidisciplinary decision-making on teaching or de-identified cases; they are not a substitute for a patient's own care team.